Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The last time I posted on Gilead Sciences, Inc. ( GILD ), the California-based Pharma giant, and a company I am invested in, it was to cover its Q1 2025 earnings andEdmund Ingham is a biotech consultant. He has bee ...